Nasdaq
$71.47▼ 0.29%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $9.07BShares out 1.300M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
24- 10.7After-hours26.10.08 06:02SCHEDULE 13G/AOwnership#●●●
10x Genomics, Inc.
ARK Investment Management LLC and Catherine D. Wood have filed Amendment No. 4 to their Schedule 13G regarding their ownership of 10x Genomics, Inc. common stock. This filing formalizes the joint reporting agreement between the two parties concerning their holdings in the issuer.…more
$71.47-0.29%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.24After-hours26.09.25 05:304Ownership
10x Genomics, Inc.
10x Genomics executive Suliman Shehnaaz reported a change in beneficial ownership of securities as of September 22, 2026. This filing serves as a Form 4 statement regarding the insider's stock holdings.…more
$71.47-0.29%vs prev closeView filingShare - 9.24After-hours26.09.25 05:294Ownership
10x Genomics, Inc.
Serge Saxonov, CEO of 10x Genomics, filed a Form 4 on September 24, 2026, reporting the disposal of company shares that occurred on September 22, 2026. This filing serves as a standard disclosure of insider equity transactions.…more
$71.47-0.29%vs prev closeView filingShare
23 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.7Pre-market26.10.07 22:05#●●●#●●●
10x Genomics Partners With Fred Hutchinson Cancer Center for Cancer Research…more
10x Genomics has entered into a multi-project research collaboration with Fred Hutchinson Cancer Center. The partnership aims to advance the application of single cell and spatial technologies in treating solid tumors and hematologic malignancies.…more
$71.47-0.29%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.29Pre-market26.09.29 22:08
●●●●●●●● ●●●●● ●●●●●●
10x Genomics has introduced the Sentira platform, which utilizes NVIDIA accelerated computing to reduce spatial data processing time from hours to minutes. While this new product enhances research efficiency, it is classified as neutral due to the lack of specific revenue impact data.…more
$71.47-0.29%vs prev closeShareBenzinga - 9.10Pre-market26.09.10 22:04
●●●●●●●● ●●●●● ●●●●●●
Lunit's AI-powered pathology platform, Lunit SCOPE IO, will be integrated into 10x Genomics' oncology biomarker discovery workflow. This collaboration aims to enhance precision medicine research by combining spatial molecular data with AI-driven pathology image analysis.…more
$71.47-0.29%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report